BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨

路透中文

Jan 20

BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨

1月20日 - ** 澳大利亚泰利克斯制药公司（Telix Pharmaceuticals）TLX.AX股价上涨6.3%至11.99澳元，创下近两个月来最大盘中涨幅。

** 股价触及12月底以来的最高水平

** 生物制药公司称，中国国家医药管理局(NMPA) 已经受理了 (link) 其前列腺癌诊断药物Illuccix的新药申请(NDA)

** 称已与大中华区合作伙伴广药集团0512.HK联合提交新药申请

** Illuccix 用作扫描剂，检测体内的前列腺癌

** 澳大利亚基准指数.AXJO下跌0.5%，TLX涨幅居前

** 在2025年下跌54.5%之后，TLX在年度内上涨了4.6%。

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2604055151"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2604055151\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2604055151?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-20 08:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604055151","market":"us","top_or_hot":-1,"title":"BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨</title></head><body><p>\n<span>1月20日</span><span> - </span>** 澳大利亚泰利克斯制药公司（<a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>）<span>TLX.AX</span>股价上涨6.3%至11.99澳元，创下近两个月来最大盘中涨幅。</p><p>** 股价触及12月底以来的最高水平</p><p>** 生物制药公司称，中国国家医药管理局(NMPA) 已经受理了 (<span>link</span>) 其前列腺癌诊断药物Illuccix的新药申请(NDA) </p><p>** 称已与<a href=\"https://laohu8.com/S/00021\">大中华</a>区合作伙伴广药集团<span>0512.HK</span>联合提交新药申请 </p><p>** Illuccix 用作扫描剂，检测体内的前列腺癌</p><p>** 澳大利亚基准指数<span>.AXJO</span>下跌0.5%，TLX涨幅居前</p><p>** 在2025年下跌54.5%之后，TLX在年度内上涨了4.6%。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-20 08:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨</title></head><body><p>\n<span>1月20日</span><span> - </span>** 澳大利亚泰利克斯制药公司（<a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>）<span>TLX.AX</span>股价上涨6.3%至11.99澳元，创下近两个月来最大盘中涨幅。</p><p>** 股价触及12月底以来的最高水平</p><p>** 生物制药公司称，中国国家医药管理局(NMPA) 已经受理了 (<span>link</span>) 其前列腺癌诊断药物Illuccix的新药申请(NDA) </p><p>** 称已与<a href=\"https://laohu8.com/S/00021\">大中华</a>区合作伙伴广药集团<span>0512.HK</span>联合提交新药申请 </p><p>** Illuccix 用作扫描剂，检测体内的前列腺癌</p><p>** 澳大利亚基准指数<span>.AXJO</span>下跌0.5%，TLX涨幅居前</p><p>** 在2025年下跌54.5%之后，TLX在年度内上涨了4.6%。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4S3YL01L:1","article_id":"2604055151","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604055151","pubTimestamp":1768869597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"1月20日 - ** 澳大利亚泰利克斯制药公司TLX.AX股价上涨6.3%至11.99澳元，创下近两个月来最大盘中涨幅。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK1191":"制药","BK4157":"电子设备和仪器","00512":"远大医药","BK7067":"生物科技","TNLX":"Trans-Lux Corp."},"translate_title":"BUZZ-Australia's Telix Pharmaceuticals rises on China accepting new drug applications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9,"TLX.AU":0.9,"TNLX":0.9},"content_text":"BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨\n1月20日 - ** 澳大利亚泰利克斯制药公司（Telix Pharmaceuticals）TLX.AX股价上涨6.3%至11.99澳元，创下近两个月来最大盘中涨幅。** 股价触及12月底以来的最高水平** 生物制药公司称，中国国家医药管理局(NMPA) 已经受理了 (link) 其前列腺癌诊断药物Illuccix的新药申请(NDA) ** 称已与大中华区合作伙伴广药集团0512.HK联合提交新药申请 ** Illuccix 用作扫描剂，检测体内的前列腺癌** 澳大利亚基准指数.AXJO下跌0.5%，TLX涨幅居前** 在2025年下跌54.5%之后，TLX在年度内上涨了4.6%。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}